CEBPA and acute myeloid leukemia: Biallelic CEBPA (biCEBPA) mutations are detected in 2-15% of de novo acute myeloid leukemia (AML) patients, and are associated with a favorable clinical outcome compared to wildtype or monoallelic CEBPA mutation (3).